ADIL Company Profile and Key Details

Short-term trend indicators are bullishly aligned (SMA20 -24.01%, SMA50 -48.18%, SMA200 -71.31%). The stock’s 14-day RSI is 19.19 (weak momentum), while the ATR of 0.38 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -91.64% below its high and over 11.45% above its low. Average 10-day trading volume of 480.38 thousand shares is significantly above the 3-month average of 64.03 thousand, indicating heightened recent market interest.

Adial Pharmaceuticals, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $5.04. This means the shares are trading below this model’s fair value.

Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) closed at $1.72 USD, losing -$0.11 (-6.01%) from the previous close of $1.83. The stock is currently mid-range between its 52-week high and low $1.54 and $30.25. With a market capitalization of about $1.65 million, Adial Pharmaceuticals, Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~1.32). Key stats such as the average daily volume over the past year has been around 70.24 thousand shares, trading with heavier-than-usual volume. Headquartered in Charlottesville, VA, Adial Pharmaceuticals, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Cary John Claiborne, the company employs approximately 5 people and listed since July 27, 2018. Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders.

Adial Pharmaceuticals, Inc. generated EPS of -$23.15 over the past year. Five-year average earnings growth is 34.05%. Wall Street analysts project EPS growth of 65.97% annually over the next five years. The latest quarter delivered EPS of -$0.08. The next quarter is forecast at -$2.13. Next year's EPS is expected at $73.26. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 1 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $1.50 to $1.50. The high target offers -12.79% upside. The low target suggests -12.79% downside. The mean target is $1.50. This offers -12.79% upside. Adial Pharmaceuticals, Inc. earnings surprise history is frequent misses against expectations. The quarter that ended November 13, 2025, missed forecasts by -11.11%. The prior quarter beat by -18.18%. Over the last six quarters, Apple has recorded several small beats. These include 51.28% in August 13, 2024.

Adial Pharmaceuticals, Inc. has 1.11 million shares outstanding. The public float is 858.25 thousand shares, elevated short interest at 3.04% of float. This equals 33.64 thousand shares. The short ratio is 0.82 days. Institutional investors hold 4.03% of the float. Insiders own 2.24%. Stilley William B. III holds 937.65 thousand shares, Johnson Bankole A. has 148.25 thousand shares and Gilliland Robertson H. has 43.93 thousand shares.

Adial Pharmaceuticals, Inc. trades at a P/E ratio of -0.23, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 0.34 suggesting the stock is closer to book value. The P/FCF stands at -0.24, also above market averages.

Our AI price prediction model suggests that Adial Pharmaceuticals, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -71.51%, with price expected at $0.49 by March 23, 2026, within a range of $0.00 to $1.12 3-Month Outlook: Projected fall of -49.42%, reaching $0.87 by June 05, 2026, with a range of $0.42 to $1.28. 1-Year Outlook: Projected loss of -56.4%, with price at $0.75 by March 09, 2027, within a range of $0.00 to $4.57.

Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) shares are flat -1.68% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Adial Pharmaceuticals, Inc. trading at a premium to the broader market with a P/E of -0.23. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $4.17, suggesting 142.44% upside. Our AI forecast model points to short-term weakness (-71.51% over two weeks), a medium-term fall (-49.42% over three months), and a longer-term loss (-56.4% over one year), with expected trading ranges indicating moderate volatility.